Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALEXANDRIA REAL ESTATE EQUITIES, INC.ARE · Entity 419 | Director · Executive Chairman | September 11, 2026 | September 15, 2026 |
| Applied Therapeutics, Inc.APLT · Entity 67708 | Director | June 06, 2024 | June 07, 2024 |
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director | March 15, 2019 | March 19, 2019 |
| Korro Bio, Inc.FREQ · Entity 6388 | Director | August 17, 2022 | August 19, 2022 |
| MeiraGTx Holdings plcMGTX · Entity 4734 | Director | June 07, 2022 | June 09, 2022 |
| TRex Bio, Inc.TRXB · Entity 184308 | Director | October 13, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALEXANDRIA REAL ESTATE EQUITIES, INC.
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 597,724 |
Reported balance
After 2026-09-11 transaction · row 1
1 source rowRow 1 · 2026-09-11 · Purchase · Acquired 5,000 · Balance 597,724 F1: The shares were purchased at prices ranging from $49.38 to $49.82. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were purchased at prices ranging from $49.38 to $49.82. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Applied Therapeutics, Inc.
Report date June 06, 2024 · Filed June 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 498,414 |
Reported balance
After 2024-06-06 transaction · row 1
1 source rowRow 1 · 2024-06-06 · Grant · Acquired 45,000 · Balance 498,414 F1: Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the Restricted Stock Units shall vest on a quarterly basis from June 6, 2024 until the earlier of (i) the first anniversary of the date of grant and (ii) the date of the issuer's next annual stockholder meeting, in each case, subject to the reporting person's continuous service as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the Restricted Stock Units shall vest on a quarterly basis from June 6, 2024 until the earlier of (i) the first anniversary of the date of grant and (ii) the date of the issuer's next annual stockholder meeting, in each case, subject to the reporting person's continuous service as of each such date.
Atara Biotherapeutics, Inc.
Report date March 15, 2019 · Filed March 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 888,355 |
Reported balance
After 2019-03-15 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-03-15 · Sale · Disposed 20,000 · Balance 888,355 F1: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.10 to $38.56. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F2: Consists of shares of common stock held by Alexandria Equities, LLC. Mr. Marcus is the Chairman, CEO and Founder of Alexandria Real Estate Equities, Inc., which is the managing member of Alexandria Equities, LLC, which has full voting and investment power with respect to the shares owned by Alexandria Equities, LLC. As an officer of Alexandria Real Estate Equities, Inc., Mr. Marcus may be deemed to have voting and investment power with respect to the shares owned by Alexandria Equities, LLC. Mr. Marcus disclaims beneficial ownership of the shares held by Alexandria Equities, LLC, except to the extent of his underlying pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectHeld by the Joel S. Marcus and Barbara A. Marcus Family Trust | 4,000 |
Reported balance
Holding disclosure · report date 2019-03-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,000 |
| Common StockSEC Table I · non-derivative | Direct | 7,500 |
Reported balance
Holding disclosure · report date 2019-03-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,500 |
Filing footnotes · ownership attribution and instrument terms
F1: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.10 to $38.56. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F2: Consists of shares of common stock held by Alexandria Equities, LLC. Mr. Marcus is the Chairman, CEO and Founder of Alexandria Real Estate Equities, Inc., which is the managing member of Alexandria Equities, LLC, which has full voting and investment power with respect to the shares owned by Alexandria Equities, LLC. As an officer of Alexandria Real Estate Equities, Inc., Mr. Marcus may be deemed to have voting and investment power with respect to the shares owned by Alexandria Equities, LLC. Mr. Marcus disclaims beneficial ownership of the shares held by Alexandria Equities, LLC, except to the extent of his underlying pecuniary interest therein.
Korro Bio, Inc.
Report date August 17, 2022 · Filed August 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2030-06-10 | Direct | 14,846 |
Reported balance
After 2022-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-17 · Grant · Acquired 14,846 · Balance 14,846 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F1: The option vested in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $18.63 · Expires 2030-06-10 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-17 · Disposition to issuer · Disposed 14,846 · Balance 0 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F3: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-06-16 | Direct | 14,846 |
Reported balance
After 2022-08-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-17 · Grant · Acquired 14,846 · Balance 14,846 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F4: The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.14 · Expires 2031-06-16 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-17 · Disposition to issuer · Disposed 14,846 · Balance 0 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F5: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders
F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.
F3: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders
F4: The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.
F5: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.
MeiraGTx Holdings plc
Report date June 07, 2022 · Filed June 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.25 · Expires 2032-06-07 | Direct | 15,000 |
Reported balance
After 2022-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-07 · Grant · Acquired 15,000 · Balance 15,000 F1: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 15,000 |
Reported balance
After 2022-06-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-07 · Grant · Acquired 15,000 · Balance 15,000 F2: Each restricted share unit converts into one ordinary share upon vesting. F3: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023.
F2: Each restricted share unit converts into one ordinary share upon vesting.
F3: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023.
TRex Bio, Inc.
Report date October 13, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,871 |
Reported balance
After 2026-10-13 transaction · row 1
1 source rowRow 1 · 2026-10-13 · Conversion · Acquired 41,871 · Balance 41,871 F1: On October 13, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 3.8649-to-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-10-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-13 · Conversion · Disposed 161,828 · Balance 0 F1: On October 13, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 3.8649-to-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 13, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 3.8649-to-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Intra-Cellular Therapies, Inc.
Report date April 02, 2025 · Filed April 02, 2025
Section 16 reporting ended · disclosed 2025-04-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 1
1 source rowRow 1 · 2025-04-02 · Disposition to issuer · Disposed 48,238 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2025-04-02 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-04-02 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. F3: Represents securities held of record by Alexandria Real Estate Equities, Inc. The reporting person is the Executive Chairman & Founder of Alexandria Real Estate Equities, Inc. and may therefore be deemed to have voting and investment power with respect to the shares owned by Alexandria Real Estate Equities, Inc. The reporting person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.77 · Expires 2034-06-13 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-04-02 · Disposition to issuer · Disposed 4,322 · Balance 0 F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-04-02 · Disposition to issuer · Disposed 2,951 · Balance 0 F6: Each restricted stock unit (each, a "Company RSU") represented a contingent right to re-ceive one Company Share. F7: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F8: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").
F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.
F3: Represents securities held of record by Alexandria Real Estate Equities, Inc. The reporting person is the Executive Chairman & Founder of Alexandria Real Estate Equities, Inc. and may therefore be deemed to have voting and investment power with respect to the shares owned by Alexandria Real Estate Equities, Inc. The reporting person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.
F6: Each restricted stock unit (each, a "Company RSU") represented a contingent right to re-ceive one Company Share.
F7: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.
F8: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2019 Filed Oct 8, 2019 00:30 UTC | Korro Bio, Inc. FREQ · Entity 6388 | ConversionCommon Stock | 617,916 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-025213 · doc4.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Alexandria Venture Investments, LLC Disclosed balance after: 956,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 00:30 UTC | Korro Bio, Inc. FREQ · Entity 6388 | ConversionCommon Stock | 352,509 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-025213 · doc4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. Read SEC document |
| September 27, 2019 Filed Oct 1, 2019 20:47 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 7,500 | $154.49 | $1,158,675.00 |
DisclosureSEC source: 0001035443-19-000252 · wf-form4_156996280026592.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,462 F1 · price: The shares were sold at prices ranging from $154.39 to $154.57. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 06, 2019 Filed Sep 10, 2019 21:05 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 9,750 | $152.75 | $1,489,312.50 |
DisclosureSEC source: 0001035443-19-000239 · wf-form4_156814954313824.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,962 F1 · price: The shares were sold at prices ranging from $152.66 to $153.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 21:19 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 10,000 | $144.85 | $1,448,500.00 |
DisclosureSEC source: 0001035443-19-000217 · wf-form4_156564477839050.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,712 F2 · price: The shares were sold at prices ranging from $144.81 to $145.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:19 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 15,000 | $146.65 | $2,199,750.00 |
DisclosureSEC source: 0001035443-19-000217 · wf-form4_156564477839050.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,712 F1 · price: The shares were sold at prices ranging from $146.47 to $147.01. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2019 Filed Aug 5, 2019 20:38 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 15,000 | $144.80 | $2,172,000.00 |
DisclosureSEC source: 0001035443-19-000199 · wf-form4_156503749781754.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,712 F1 · price: The shares were sold at prices ranging from $144.58 to $145.02. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 20:38 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 5,000 | $146.00 | $730,000.00 |
DisclosureSEC source: 0001035443-19-000199 · wf-form4_156503749781754.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,712 Read SEC document |
| June 25, 2019 Filed Jun 26, 2019 20:47 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantRestricted Stock Units · Derivative | 14,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039119 · doc4.xml · derivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,005 Underlying: Common Stock · 14,005 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: On June 25, 2019, the reporting person was granted 14,005 restricted stock units, vesting on the first anniversary of the grant date (June 25, 2020). F2 · derivative.expiration_date: On June 25, 2019, the reporting person was granted 14,005 restricted stock units, vesting on the first anniversary of the grant date (June 25, 2020). Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:16 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $21.28 | $0.00 |
DisclosureSEC source: 0000899243-19-017801 · doc4.xml · derivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 25,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 19, 2020 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2020. Read SEC document |
| June 18, 2019 Filed May 13, 2022 21:24 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionRestricted Stock Units · Derivative | 14,189 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028919 · doc4.xml · derivative · entry 4 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,189 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: On June 18, 2018, the reporting person was granted 14,189 restricted stock units, vesting on the first anniversary of the grant date (June 18, 2019). F5 · derivative.expiration_date: On June 18, 2018, the reporting person was granted 14,189 restricted stock units, vesting on the first anniversary of the grant date (June 18, 2019). Read SEC document |
| June 18, 2019 Filed May 13, 2022 21:24 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionCommon Stock | 14,189 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-028919 · doc4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · balance_after: Includes 7,297 shares previously reported as sold from the reporting person's direct holdings, which were actually sold by Alexandria Real Estate Equities, Inc. Read SEC document |
| May 31, 2019 Filed May 31, 2019 20:35 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033664 · doc4.xml · nonDerivative · entry 3 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Joel S. Marcus and Barbara A. Marcus Family Trust Disclosed balance after: 98,742 F1 · kind: On May 31, 2019, the aggregate of 20,000 shares of common stock acquired by Mr. Marcus upon the exercise of stock options on May 29, 2019 was transferred for no consideration to the Joel S. Marcus and Barbara A. Marcus Family Trust. Read SEC document |
| May 31, 2019 Filed May 31, 2019 20:35 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033664 · doc4.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,671 F1 · kind: On May 31, 2019, the aggregate of 20,000 shares of common stock acquired by Mr. Marcus upon the exercise of stock options on May 29, 2019 was transferred for no consideration to the Joel S. Marcus and Barbara A. Marcus Family Trust. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:35 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $12.45 | $0.00 |
DisclosureSEC source: 0001209191-19-033664 · doc4.xml · derivative · entry 6 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2027-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:35 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionCommon Stock | 20,000 | $12.45 | $249,000.00 |
DisclosureSEC source: 0001209191-19-033664 · doc4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2019 Filed May 20, 2019 21:08 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | ConversionSeries B Preferred Stock · Derivative | 135,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-031450 · doc4.xml · derivative · entry 5 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 135,192 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019. Read SEC document |
| May 16, 2019 Filed May 20, 2019 21:08 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | ConversionSeries A Preferred Stock · Derivative | 110,497 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-031450 · doc4.xml · derivative · entry 4 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,497 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019. Read SEC document |
| May 16, 2019 Filed May 20, 2019 21:08 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | PurchaseCommon Stock | 150,000 | $10.00 | $1,500,000.00 |
DisclosureSEC source: 0001209191-19-031450 · doc4.xml · nonDerivative · entry 3 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,860 Read SEC document |
| May 16, 2019 Filed May 20, 2019 21:08 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | ConversionCommon Stock | 135,192 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-031450 · doc4.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019. Read SEC document |
| May 16, 2019 Filed May 20, 2019 21:08 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | ConversionCommon Stock | 110,497 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-031450 · doc4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's common stock, without payment of additional consideration, on a one-for-one basis, immediately upon the closing of the Issuer's initial public offering on May 16, 2019. Read SEC document |
| May 13, 2019 Filed May 15, 2019 21:10 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | GrantStock Option (right to buy) · Derivative | 20,460 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030080 · doc4.xml · derivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,460 Underlying: Common Stock · 20,460 shares Expires 2029-05-12 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares subject to the Option shall vest each month commencing on June 13, 2019, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 08, 2019 Filed May 10, 2019 20:43 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 8,500 | $140.67 | $1,195,695.00 |
DisclosureSEC source: 0001035443-19-000137 · wf-form4_155752097876105.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,712 F1 · price: The shares were sold at prices ranging from $140.67 to $140.68. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:12 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 15,000 | $142.03 | $2,130,450.00 |
DisclosureSEC source: 0001035443-19-000132 · wf-form4_155717713179843.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 509,212 F1 · price: The shares were sold at prices ranging from $141.67 to $142.41. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 20:47 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | GrantCommon Stock | 21,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001035443-19-000100 · wf-form4_155423802324933.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 524,212 Read SEC document |
| March 28, 2019 Filed Mar 29, 2019 20:34 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 10,000 | $142.83 | $1,428,300.00 |
DisclosureSEC source: 0001035443-19-000079 · wf-form4_155389166932117.xml · nonDerivative · entry 3 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 502,312 F3 · price: The shares were sold at prices ranging from $142.78 to $142.94. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 28, 2019 Filed Mar 29, 2019 20:34 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 10,000 | $142.00 | $1,420,000.00 |
DisclosureSEC source: 0001035443-19-000079 · wf-form4_155389166932117.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 512,312 F2 · price: The shares were sold at prices ranging from $141.89 to $142.22. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 20:34 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 25,000 | $142.39 | $3,559,750.00 |
DisclosureSEC source: 0001035443-19-000079 · wf-form4_155389166932117.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,312 F1 · price: The shares were sold at prices ranging from $142.31 to $142.51. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 20:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 20,000 | $38.25 | $765,000.00 |
DisclosureSEC source: 0001209191-19-020276 · doc4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 888,355 F1 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.10 to $38.56. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F2 · ownership.nature: Consists of shares of common stock held by Alexandria Equities, LLC. Mr. Marcus is the Chairman, CEO and Founder of Alexandria Real Estate Equities, Inc., which is the managing member of Alexandria Equities, LLC, which has full voting and investment power with respect to the shares owned by Alexandria Equities, LLC. As an officer of Alexandria Real Estate Equities, Inc., Mr. Marcus may be deemed to have voting and investment power with respect to the shares owned by Alexandria Equities, LLC. Mr. Marcus disclaims beneficial ownership of the shares held by Alexandria Equities, LLC, except to the extent of his underlying pecuniary interest therein. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 21:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 62,590 | $36.07 | $2,257,621.30 |
DisclosureSEC source: 0001209191-19-014941 · doc4.xml · nonDerivative · entry 5 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.75 to $36.72. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0001209191-19-014941 · doc4.xml · derivative · entry 11 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,500 shares Expires 2024-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,500 | $0.00 Strike: $15.08 | $0.00 |
DisclosureSEC source: 0001209191-19-014941 · doc4.xml · derivative · entry 10 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,500 shares Expires 2024-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 10,500 | $0.00 Strike: $24.05 | $0.00 |
DisclosureSEC source: 0001209191-19-014941 · doc4.xml · derivative · entry 9 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,500 shares Expires 2023-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $25.15 | $0.00 |
DisclosureSEC source: 0001209191-19-014941 · doc4.xml · derivative · entry 8 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 21,500 | $13.20 | $283,800.00 |
DisclosureSEC source: 0001209191-19-014941 · doc4.xml · nonDerivative · entry 4 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 5,500 | $15.08 | $82,940.00 |
DisclosureSEC source: 0001209191-19-014941 · doc4.xml · nonDerivative · entry 3 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 10,500 | $24.05 | $252,525.00 |
DisclosureSEC source: 0001209191-19-014941 · doc4.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 25,000 | $25.15 | $628,750.00 |
DisclosureSEC source: 0001209191-19-014941 · doc4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 21:36 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 10,000 | $134.41 | $1,344,100.00 |
DisclosureSEC source: 0001035443-19-000057 · wf-form4_155069859881005.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 547,312 F1 · price: The shares were sold at prices ranging from $134.31 to $134.58. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 21:41 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 10,000 | $130.01 | $1,300,100.00 |
DisclosureSEC source: 0001035443-19-000043 · wf-form4_154992125404979.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 557,312 F1 · price: The shares were sold at prices ranging from $130.00 to $130.14. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 21:38 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | GrantCommon Stock | 30,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001035443-19-000022 · wf-form4_154784748286795.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 567,312 Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 21:47 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 10,000 | $126.26 | $1,262,600.00 |
DisclosureSEC source: 0001035443-18-000239 · wf-form4_154473763913421.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,255 F1 · price: The shares were sold at prices ranging from $126.00 to $126.52. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 21:45 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 5,000 | $125.00 | $625,000.00 |
DisclosureSEC source: 0001035443-18-000234 · wf-form4_154395988283556.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 547,255 Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 21:45 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 5,000 | $124.25 | $621,250.00 |
DisclosureSEC source: 0001035443-18-000234 · wf-form4_154395988283556.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,255 F1 · price: The shares were sold at prices ranging from $124.24 to $124.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 22:34 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | SaleCommon Stock | 7,000 | $17.94 | $125,580.00 |
DisclosureSEC source: 0001209191-18-058348 · doc4.xml · nonDerivative · entry 3 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Joel S. Marcus and Barbara A. Marcus Family Trust Disclosed balance after: 78,742 Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 22:34 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | SaleCommon Stock | 25,000 | $18.24 | $456,000.00 |
DisclosureSEC source: 0001209191-18-058348 · doc4.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Joel S. Marcus and Barbara A. Marcus Family Trust Disclosed balance after: 85,742 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.0280 to $18.4750, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 21:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 10,000 | $36.35 | $363,500.00 |
DisclosureSEC source: 0001209191-18-057739 · doc4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,590 F1 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.201 to $36.641. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 06, 2018 Filed Nov 8, 2018 21:38 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 5,000 | $122.81 | $614,050.00 |
DisclosureSEC source: 0001035443-18-000223 · wf-form4_154171306452147.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 557,255 Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 21:33 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 10,000 | $123.02 | $1,230,200.00 |
DisclosureSEC source: 0001035443-18-000219 · wf-form4_154145358067940.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 562,255 F1 · price: The shares were sold at prices ranging from $123.00 to $123.13. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:01 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 10,000 | $128.38 | $1,283,800.00 |
DisclosureSEC source: 0001035443-18-000182 · wf-form4_153497168266711.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 572,255 F1 · price: The shares were sold at prices ranging from $128.37 to $128.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.